Refractory Cutaneous Melanoma
2 clinical trials · Condition
◉ Watch Refractory Cutaneous Melanoma
| Record | Firm | Date |
|---|---|---|
| Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma (NCT05200143) | Providence Health & Services | 2022-06-08 |
| Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (NCT03420963) | M.D. Anderson Cancer Center | 2018-08-31 |
Track Refractory Cutaneous Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.